About Us

Together, we can advance innovation, expand access to care and empower people to live well.

About the Foundation

Our Board

Foundation Team

Contact Us

Photo of Riggs BUMC ED exterior

Cancer care

Propel advances in cancer research and treatment, bringing hope and healing to patients.

Capital & technology

Invest in the future of healthcare by helping expand and modernize our North Texas facilities.

Community health

Expand access to compassionate healthcare for underserved individuals and families.

Graduate medical education

Shape the future of medicine by helping train the next generation of physicians.

In your region

Make a direct impact on Baylor Scott & White hospitals and patients in your community.

Patient programs

Help enhance patient well-being through innovative, patient-centered programs.

Research

Help drive discoveries and improve patient outcomes by supporting accessible research and clinical trials.

Transplant

Support life-changing care for transplant patients and their families.

Donate online

Your gift can make an immediate difference in the lives of those we serve.

Grateful Giving

Patients and loved ones can show appreciation for the caregivers who made a difference during their healthcare experience.

Make a planned gift

Learn about the multiple ways to make a planned gift and create a lasting legacy.

Giving societies

Giving societies honor donors for their generosity in empowering people to live well.

Celebrating Women

Help us advance the fight against breast cancer through Celebrating Women.

Grand Rounds

Support graduate medical education at Baylor Scott & White by participating in the Ground Rounds golf tournament.

Grand Rounds Golf Tournament logo

The Compass

Read the latest issue of The Compass, a quarterly newsletter from the Baylor Scott & White Dallas Foundation.

Texas Immuno-Oncology Biorepository 

Cancer research is evolving rapidly, and the Texas Immuno-Oncology Biorepository (TIOB) is at the forefront of transformational immunology research. By studying biological samples from diverse populations, researchers at Baylor Scott & White Health are unlocking insights that may lead to earlier cancer detection, improved treatments, and innovative immunotherapies. 

Unlocking the future of cancer treatment

Less than 10% of adults with cancer participate in clinical trials, yet much of our research is based on findings from this small subset of patients—patients who are often younger, healthier, and not fully representative of the broader population affected by cancer. As a result, critical gaps remain in our understanding of how cutting-edge treatments, particularly immunotherapies, work in real-world settings across diverse patient populations. 

Breaking barriers to personalized cancer treatment

While immunotherapy has revolutionized cancer care, its success remains unpredictable—some patients achieve long-term remission, while others see little to no benefit. The reason? We simply don’t know enough about the biological factors that drive treatment response. 

Without a deeper understanding of how immunotherapies work across diverse populations in real-world settings, we risk leaving too many patients behind.  

The Texas Immuno-Oncology Biorepository (TIOB) at Baylor Scott & White Research Institute (BSWRI) was created to bridge this gap. Launched in 2020 with significant philanthropic support, the TIOB has grown rapidly, collecting biospecimens from patients across multiple locations to advance our understanding of immunotherapy and drive the future of personalized cancer treatment.

Learning from each patient we care for

Every patient’s cancer journey is unique, yet current treatments often take a one-size-fits-all approach. The TIOB is helping to change this by providing researchers with critical biological samples—blood, urine, tissue, and stool—collected from a diverse patient population. These samples allow scientists to uncover key insights, including: 

  • How different cells and immune systems respond to cancer treatment 
  • Why some cancers resist treatment or return after remission 
  • Whether genomic, racial, or environmental factors influence treatment outcomes across diverse populations 
  • How to enhance patient response and survival rates through more personalized approaches 

These initiatives are paving the way for more precise, personalized immunotherapies, ensuring that more patients can benefit from life-saving treatments. In alignment with Baylor Scott & White’s effort to intercept early-stage cancers, the TIOB also plays a critical role in the Texas Cancer Interception Institute. With continued investment, TIOB can deepen our understanding of these complexities, leading to better treatments and more lives saved. 

Your role in changing the future of cancer care

Research is vital to improving cancer prevention, early detection and targeted therapies and philanthropy plays a crucial role in accelerating these discoveries.  

The TIOB’s scope, scale and opportunity for impact has resulted in generous support from forward-thinking philanthropic funders who helped launch and grow this effort. 

Your gift can further expand the reach and impact of this important work and help bring more effective treatments to real patients across Texas. 

Featured stories

Read more about how the TIOB is opening the doors to new therapeutic insights and advances in personalized medicine.

Texas Immuno-Oncology Biorepository Launches Inaugural Research Study

Texas Immuno-Oncology Biorepository Launches Inaugural Research Study

March 1, 2023
Much of our current information about how to treat cancer comes from clinical trials; however, there are limits to what we can learn from trials alone. Ronan Kelly, MD, chief of oncology at Baylor Scott & White Charles A. Sammons Cancer Center and the W.W. Caruth, Jr. Chair in Immunology at Baylor University Medical Center, […]
Learn More Texas Immuno-Oncology Biorepository Launches Inaugural Research Study
Fighting cancer is in his blood—and ours

Fighting cancer is in his blood—and ours

June 1, 2024
Baylor Scott & White Health chief of oncology demonstrates that immunotherapy combined with chemotherapy and radiation prior to surgical resection of a tumor, is safe while also demonstrating how to track tumor responses utilizing a novel blood test. Dr. Ronan Kelly · Chief of oncology for Baylor Scott & White Health in North Texas Understanding […]
Learn More Fighting cancer is in his blood—and ours
Multi-Cancer Early Detection Program

Multi-Cancer Early Detection Program

September 1, 2024
With an aim of intercepting cancers in Texans earlier, the program includes approximately 50,000 MCED tests being administered to BSW patients across North Texas.
Learn More Multi-Cancer Early Detection Program